A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Assess the Efficacy of Tadalafil (CialisÂ®) in the Treatment of Erectile Dysfunction after External-Beam Radiotherapy for Prostatic Cancer
Comparison between tadalafil scores and placebo scores was done using Wilcoxon’s matched pairs test. For within- and between-group comparison of percentages, McNemar’s test and Fisher’s exact test were used, respectively. Results: Mean age at study entry was 69 years. All patients completed the study. There was a significant increase in mean scores from baseline with tadalafil, but not with placebo. For all the IIEF domains there was a statistically significant difference between tadalafil and placebo. Sixty-seven percent of the patients reported an improvement of erectile function with tadalafil (placebo: 20%) and 48% reported successful intercourse with tadalafil (placebo: 9%). Side effects were mild or moderate. Except for headache, flushing and dyspepsia, all other reported adverse events did not differ significantly between the two treatments.
Tadalafil is an effective treatment for erectile dysfunction after EBRT for prostatic cancer with successful intercourse reported in almost 50% of the patients, and is well tolerated.